



# Biotech Daily

Wednesday October 12, 2022

*Daily news on ASX-listed biotechnology companies*

- \* **ASX FLAT, BIOTECH DOWN: CYCLOPHARM UP 17%;  
- COMPUMEDICS DOWN 10%**
- \* **SAFETY REVIEW APPROVES CYNATA DIABETIC FOOT ULCER TRIAL**
- \* **EXOPHARM TO TAKE 2 EXOSOMES TO PRE-CLINICAL TRIALS**
- \* **CRONOS COMMISSIONS MELBOURNE MARIJUANA WAREHOUSE**
- \* **BOTANIX REQUESTS 'TRIAL RESULTS' TRADING HALT**
- \* **CSL ANNUAL GENERAL MEETING FACES 10% DISSENT**
- \* **2 WEEKS TO AUSBIOTECH, AUSBIOINVEST**
- \* **MARK, LINDA KERR TAKE 6.4% OF CRYOSITE**
- \* **OVENTUS ADMINISTRATORS APPOINT DR MELVYN BRIDGES DIRECTOR**

## MARKET REPORT

The Australian stock market edged up 0.04 percent on Wednesday October 12, 2022, with the ASX200 up 2.5 points to 6,647.5 points.

Nine of the Biotech Daily Top 40 companies were up, 20 fell, seven traded unchanged and four were untraded. All three Big Caps fell.

Cyclopharm was the best, up 21.5 cents or 16.6 percent to \$1.51, with 38,364 shares traded. Cynata and Universal Biosensors climbed more than five percent; Starpharma improved 3.3 percent; Kazia and Orthocell rose more than two percent; Immutep was up 1.8 percent; with Clinuvel and Pro Medicus up by less than one percent.

Compumedics led the falls, down 2.5 cents or 10.4 percent to 21.5 cents, with 26,594 shares traded.

Actinogen fell a further seven percent; Alcidion, Atomo, Dimerix, Medical Developments, Mesoblast, Oncosil, Pharmaxis, Polynovo and Telix lost more than three percent; Cochlear, Emvision, Imugene, Opthea, Paradigm and Patrys shed more than two percent; CSL, Neuren and Volpara were down more than one percent; with Nanosonics, Proteomics and Resmed down by less than one percent.

## CYNATA THERAPEUTICS

Cynata says a review of safety data has approved the continuation of its 30-patient trial of CYP-006TK stem cell wound dressing for diabetic foot ulcers.

In April, Cynata said it had enrolled the first patients in its phase I trial of CYP-006TK mesenchymal stem cell wound treatment (BD: Apr 21, 2022).

Today, the company said the study protocol for the diabetic foot ulcer clinical trial included oversight by a safety committee as well as provision for an interim review, which had been completed.

Cynata said diabetic foot ulcers were chronic wounds on the feet of patients with diabetes which could cause infection or the need for amputation.

Cynata chief medical officer Dr Jolanta Airey said data safety monitoring board's "positive recommendation is a key milestone, which enables us to continue patient enrolment as planned and to complete the trial as soon as possible".

Cynata was up two cents or 5.9 percent to 36 cents.

## EXOPHARM

Exopharm says it will advance two of its exosome drug candidates to further pre-clinical testing next year, with a view to run clinical trials of up to four products.

Exopharm said it was advancing an exosome targeting the production of the cystic fibrosis transmembrane conductance regulator protein to be delivered in nebulized form direct to the lungs of cystic fibrosis patients, as well as one which targets the elastin gene to up-regulate elastin production in skin and lungs.

Exopharm was unchanged at 13 cents.

## CRONOS AUSTRALIA

Cronos says it has commissioned a distribution centre in Melbourne and secured the Victoria Government licences to supply products from the site.

Cronos said the new site built on the existing capacity offered by its Gold Coast Queensland distribution centre and would support "a significant uplift of the company's medicinal cannabis sales volume".

The company said the two Government licences permitted the supply of Schedule 2 products, Schedule 3 products, Schedule 4 products and Schedule 8 cannabis and tetrahydrocannabinol (THC) products to pharmacies.

Cronos chief executive operator Rodney Cocks said the two Victoria Government licences "enable the operation of our newly-commissioned Melbourne distribution centre is another important milestone for our company".

"The highly secure, state-of-the-art ... facility can support a significant uplift in medicinal cannabis sales volume through our market leading Canview platform," Mr Cocks said.

"It also puts product closer to pharmacies and patients while underpinning business continuity contingency planning," Mr Cocks said.

Cronos was up 7.5 cents or 10.6 percent to 78 cents.

## BOTANIX PHARMACEUTICALS

Botanix has requested a trading halt pending "an announcement in relation to clinical study results".

Trading will resume on October 14, 2022.

Botanix last traded at 5.9 cents.

## CSL

CSL says three of four resolutions at its annual general meeting were opposed by more than nine percent of votes.

CSL said its remuneration report was opposed by 29,533,590 votes (10.08%), with 263,377,288 votes (89.92%) percent.

The company said resolutions to re-elect director Marie McDonald and grant managing-director Paul Perreault 41,483 performance shares were opposed by 9.60 percent of votes and 9.33 percent of votes, respectively.

CSL said the re-election of Dr Megan Clark passed more easily.

According to its most recent filing, CSL has 482,216,193 shares on issue, meaning that the 29,533,590 votes opposing the remuneration report amounted to 6.12 percent of the company, sufficient to requisition extraordinary general meetings.

CSL fell \$3.16 or 1.1 percent to 279.70 with 735,418 shares traded.

## AUSBIOTECH

Ausbiotech says there are two weeks to go for the Ausbiotech and Ausbioinvest 2022 conferences in Perth, Western Australia from October 26 to 28, 2022.

Ausbiotech said Ausbioinvest was Australia's largest life sciences investment conference", with up-to 30 public and private company presentations, as well as speakers who would discuss "insights to support informed investment decisions in a complex scientific field".

The organization said that the Prof Nancy Millis Oration would be delivered by Amgen co-founder Prof Marvin Caruthers.

Ausbiotech said that keynote speakers included University of Western Australia Burns Injury Research Director Prof Fiona Wood, Telstra Health managing-director Elizabeth Koff, DLA Piper partner Dr Lisa Haile, Stanford Biodesign executive Dr Anurag Mairal and Texas Medical Center chief executive officer William McKeon.

The organization said the program was at: <https://www.ausbiotechinvestment.com.au/>.

Ausbiotech said qualified investors could apply for complimentary registration at:

<https://ausbiotech.eventsair.com/ausbiotech-2022/investor-application/Site/Register>.

The industry organization said that the three-day conference program had more than 110 speakers over 40 sessions, and would address issues "essential to growing commercial opportunities for the life sciences sector".

Ausbiotech said delegates would benefit from "from exchanging ideas, building their networks, and finding new partnerships that will drive their own business success and the ongoing development of the biotech sector in Australia" and that registration was open at:

<https://www.ausbiotechnc.org/register2022>.

Ausbiotech managing-director Lorraine Chiroiu said "our ability to attract high-quality industry experts to Ausbiotech 2022 speaks volumes for the Australian biotech sector which is providing significant economic and social value for our country, including a surge in the creation of high-value, knowledge-based jobs".

## CRYOSITE AUSTRALIA

Mark and Linda Kerr say they have increased their substantial holding in Cryosite from 2,519,413 shares (5.16%) to 3,119,465 shares (6.39%).

The Melbourne-based Kerrs said that between August 8 and October 11, they bought shares in Cryosite with the largest single acquisition 268,918 shares for \$185,553, or 68.9 cents a share.

Cryosite was untraded at 70 cents.

## OVENTUS MEDICAL

Grant Thornton says it has appointed Dr Melvyn Bridges a director of Oventus and its two Australian subsidiaries.

In June, Oventus said it had appointed Grant Thornton's Michael McCann and Graham Killer of Grant Thornton as voluntary administrators (BD: Jun 14, 2022).

Today, Grant Thornton said that in addition to Oventus, Dr Bridges would also become director of Oventus Manufacturing Pty Ltd and Oventus CRM Pty Ltd.

According to Commsec data, Dr Bridges was previously the non-executive chair of Oventus.

Grant Thornton said it expected Dr Bridges would be appointed to the role of chief executive officer and executive chair, with the terms of the roles to be finalized.

Oventus was in a suspension at two cents